Category: HeartWare International Inc.
HeartWare CEO Doug Godshall tells MassDevice.com about the 6-year journey to the $350 million acquisition of heart pump maker CircuLite.
HeartWare International acquires CircuLite in a cash-and-stock deal that could eventually be worth up to $350 million.
Shares of Thoratec Corp. slide after the New England Journal of Medicine publishes results showing a sharp increase in rates of blood clots in patients implanted with the medical device company's HeartMate II left ventricular assist device.
Thoratec (NSDQ:THOR) shares are under pressure after a New England Journal of Medicine study showing a sharp increase in the rate of thrombosis, or blood clots, in patients implanted with its HeartMate II left ventricular assist device.
HeartWare's stock gains 15% after its 3rd-quarter results crush sales and earnings forecasts on higher-than-expected sales of its heart pump.
HeartWare International (NSDQ:HTWR) shares gained 15% this morning after the medical device company crushed forecasts with its 3rd-quarter sales and earnings figures, reporting stronger-than-expected sales of its left ventricular assist device implantable heart pump.
HeartWare International plans to enroll a new arm of patients into its ongoing ENDURANCE clinical trial, this time confirming previous findings that suggest that more blood pressure management can help stem "neurological events."
Comments made by HeartWare CEO Doug Godshall seem to be in conflict with those of principal ENDURANCE trial investigator Dr. Joseph Rogers, putting analysts on edge.
Shares of HeartWare International (NSDQ:HTWR) are on watch in the wake of negative commentary from a Northland Capital Markets analyst.
Massachusetts medical device maker HeartWare is still working on its premarket approval application with the FDA, hoping new study results will help quell concerns about a higher rate of neurological events with its implantable heart pump.